Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca's Lynparza meets primary endpoint in breast cancer study A phase 3 study of AstraZeneca’s Lynparza (olaparib) met primary endpoint in a phase III trial in BRCA-mutated metastatic breast cancer. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial
By PBR Staff Writer
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
News
Oxford BioMedica’s TroVax phase I/II trial yields encouraging results
Oxford BioMedica announced that a phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) has yielded encouraging results in patients with advanced colorectal cancer (TaCTiCC).
Contract Research & Services > Clinical Trials > News

Contract Research

Novimmune, LegoChem to collaborate on antibody drug conjugate research
Swiss biotech company Novimmune and South Korea based LegoChem Biosciences (LCB) have entered into a research collaboration to evaluate an antibody drug conjugate candidate.
Contract Research & Services > Contract Research > News
Heptares Therapeutics, University of Cambridge launch research collaboration
By PBR Staff Writer
Heptares Therapeutics has partnered with the University of Cambridge to discover molecules that modulate a cardiovascular target.
Contract Research & Services > Contract Research > News

Contract Services

Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Contract Research & Services > Contract Services > News